The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
VIZO-PF BIMATOTIM 0.3/5 (AFT Pharmaceuticals Pty Ltd)
Product name
VIZO-PF BIMATOTIM 0.3/5
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
151 (255 working days)
Active ingredients
bimatoprost; timolol maleate
Registration type
New generic medicine
Indication
VIZO-PF BIMATOTIM 0.3/5 (eye drops) is indicated for the reduction of intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to monotherapy.